

EDO Principal Correspondence Control

FROM: DUE: 04/20/01

EDO CONTROL: G20010126
DOC DT: 03/28/01
FINAL REPLY:

Douglas P. Zipes
American College of Cardiology
Carl L. Tommaso
Society for Cardiac Angiography and
Interventions

TO:

Chairman Meserve

FOR SIGNATURE OF : ** GRN **

CRC NO: 01-0185

EDO

DESC:

Comments on 10 CFR Part 35, "Medical Use of
Byproduct Material"

ROUTING:

Travers
Paperiello
Kane
Norry
Reiter
Craig
Cyr/Burns

DATE: 04/02/01

ASSIGNED TO:

CONTACT:

NMSS

Virgilio

SPECIAL INSTRUCTIONS OR REMARKS:

Template Secy-017

E Pides Secy-01

OFFICE OF THE SECRETARY
CORRESPONDENCE CONTROL TICKET

EDO

Date Printed: Mar 30, 2001 16:10

PAPER NUMBER: LTR-01-0185 **LOGGING DATE:** 03/30/2001
ACTION OFFICE: EDO

AUTHOR: Douglas Zipes
AFFILIATION: ACC
ADDRESSEE: CHRM Richard Meserve
SUBJECT: Concerns 10 CFR Part 35, "Medical Use of Byproduct Material"

ACTION: Signature of EDO
DISTRIBUTION: RF

LETTER DATE: 03/28/2001
ACKNOWLEDGED: No
SPECIAL HANDLING: SECY to Ack

NOTES:
FILE LOCATION: ADAMS

DATE DUE: 04/23/2001 **DATE SIGNED:**

EDO --G20010126



March 28, 2001

The Honorable Richard A. Meserve, Chairman
United States Nuclear Regulatory Commission
One White Flint North
11555 Rockville Pike
Rockville, MD 20852-2738

Dear Chairman Meserve:

The American College of Cardiology (ACC), a medical society that represents 25,000 cardiovascular specialists, and the Society for Cardiac Angiography and Interventions (SCA&I), a medical society that represents 2000 interventional cardiologists, have been active in the revision process of 10 CFR Part 35, "Medical Use of Byproduct Material." We believe the proposed changes will maintain safety, decrease regulatory burden, and increase public confidence in the regulation of radiation.

The cardiology community has a special interest in the process, not only with respect to the use of diagnostic applications such as myocardial perfusion imaging, but also in the evolving field of intravascular radiation for restenosis prevention (intravascular brachytherapy). We believe that this modality has the potential to overcome the biggest problem associated with the interventional cardiology procedures: tissue proliferation. Intravascular radiation for restenosis prevention can be performed in many ways. We believe that current iterations of intravascular radiation are first generation tools and significant evolution of this technology will occur. We appreciate the fact the Nuclear Regulatory Commission (NRC) and Part 35 Writing Group recognizes the emerging nature of intravascular radiation for restenosis prevention.

It is important that cardiologists who take responsibility for procedures that use such sources have an appropriate knowledge base. The ACC and the SCA&I are committed to developing the curriculum and training standards for sealed sources in the vascular system. Our recommendations will include the number of cases for requisite clinical experience, amount of didactic training, reasonable clinical experience and a pathway for receiving that experience. We look forward to sharing these recommendations with the NRC once the document is complete and our Board of Trustees has approved it. In our experience, this will probably take at least 18 months to complete. Given the evolving nature of the technology, this will allow for the incorporation of new research and experience in the curriculum and training standards. In the meantime, the team approach required by the NRC and the FDA should continue.

The Honorable Richard A. Meserve
March 28, 2001
Page 2

The ACC and SCA&I are committed to ensuring the safety of patients and physicians using byproduct materials and believe our training recommendations will help to ensure that people using this technology are appropriately trained.

Sincerely,



Douglas P. Zipes, M.D., F.A.C.C.
President, ACC





Carl L. Tommaso, M.D., F.S.C.A.I., F.A.C.C.
President, SCA&I

cc: Commissioner Nils J. Diaz
Commissioner Greta Joy Discus
Commissioner Edward McGaffigan, Jr.
Commissioner Jeffrey S. Merrifield
Donald A. Cool, Ph.D.
Catherine Haney
Jeffrey Brinker, M.D., F.A.C.C., F.S.C.A.I.
Manuel Cerqueira, M.D., F.A.C.C.
John W. Hirshfeld, Jr., M.D., F.A.C.C., F.S.C.A.I.
Warren K. Laskey, M.D., F.A.C.C., F.S.C.A.I.
Lawrence J. Laslett, M.D., F.A.C.C.
William A. VanDecker, M.D., F.A.C.C.
George W. Vetovec, M.D., F.A.C.C., F.S.C.A.I.

AMERICAN
COLLEGE of
CARDIOLOGY



9111 Old Georgetown Road
Bethesda, MD 20814-1699 USA



The Honorable Richard A. Meserve, Chairman
United States Nuclear Regulatory Commission
One White Flint North
11555 Rockville Pike
Rockville, MD 20852-2738

20852-2738 13

